Nov 23, 2020

Public workspaceTrajectories of Glucocorticoid-Therapy After Initiation in Early (or Methotrexate-Naive) Rheumatoid Arthritis: Protocol for a Systematic Review, Meta-Analysis and Meta-Regression of Observational Cohort Studies

DOI
dx.doi.org/10.17504/protocols.io.bpyfmptn
  • 1Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Germany
Andriko Palmowski
Icon indicating open access to content
QR code linking to this content
DOI: dx.doi.org/10.17504/protocols.io.bpyfmptn
Protocol Citation: Andriko Palmowski, Frank Buttgereit 2020. Trajectories of Glucocorticoid-Therapy After Initiation in Early (or Methotrexate-Naive) Rheumatoid Arthritis: Protocol for a Systematic Review, Meta-Analysis and Meta-Regression of Observational Cohort Studies. protocols.io https://dx.doi.org/10.17504/protocols.io.bpyfmptn
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License,  which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: November 22, 2020
Last Modified: November 23, 2020
Protocol Integer ID: 44775
Objective
Objective
To assess real-world trajectories of glucocorticoid-therapy initiated as part of early rheumatoid arthritis (RA) treatment.
Eligibility
Eligibility
Observational cohort studies (CS) published between Jan 01, 2005 and now. Studies must enroll early (or methotrexate-naive) RA patients and report on those starting/taking systemic glucocorticoids (GCs) at baseline and describe at least one of our outcomes at two time points minimum.
Data Source
Data Source
MEDLINE (via PubMed).
Search Strings
Search Strings
Search strings were developed utilizing the PICOS mnemonic:

Population: early (or methotrexate-naïve) RA - Intervention: systemic GCs - Comparator: any - Outcome: any - Study design: observational cohort study
(Rheumatoid[Title] OR Arthritis, Rheumatoid[MeSh:NoExp])
AND (early[title/abstract] OR naïve[title/abstract])
AND (Cortison*[title/abstract] OR Predniso*[title/abstract] OR Cortico*[title/abstract] OR Glucocort*[title/abstract] OR Steroid*[title/abstract] OR Glucocorticoids[MeSh:NoExp])
AND (Cohort[Title/Abstract] OR Longitudinal[Title/Abstract] OR Prospective[Title/Abstract] OR Registry[Title/Abstract] OR Longitudinal Studies[Mesh:NoExp] OR Cohort Studies[Mesh:NoExp] OR Registries[Mesh:NoExp])
AND 2005/01/01:2021/01/01[dp]
NOT (random*[Title] OR randomized controlled trial[pt])
NOT (review[Title] or review[pt])
Outcomes
Outcomes
Mean/median dose of prednisone equivalent, proportion of patients who could discontinue GCs, proportion of patients who could reduce GCs (all: at baseline, 3, 6, 9, 12, and 24 months).
Data Synthesis
Data Synthesis
Meta-analysis will be conducted to pool results, including meta-regression (mixed effects) to assess change over time for each outcome.